---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300162"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:09:08.517104+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines receives termination notice from Genzyme (Sanofi) for collaboration deal

## Summary
- Genzyme terminated the June 2018 collaboration agreement for convenience; effective June 4, 2023.
- Notice received December 6, 2022; agreement had been disclosed in prior SEC filings.
- No financial impact or termination fees disclosed in the filing.
- Company may lose expected future collaboration revenue from Sanofi.

## SEC filing metadata
- accession: 0001193125-22-300162
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/0001193125-22-300162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/d426724d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300162
- JSON: https://secwatch.observer/filing/0001193125-22-300162.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300162.txt

## Key facts
- Material Agreements
  Revolution Medicines, Inc. terminated Sanofi Agreement with Genzyme Corporation (effective 2023-06-04).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Genzyme Corporation
  - Effective: 2023-06-04
  source text: On December 6, 2022, Revolution Medicines, Inc. (the “Company”) received notice of Genzyme Corporation’s decision to terminate for convenience that certain Collaborative Research, Development and Commercialization Agreement by and between the Company and Aventis, Inc., dated June 8, 2018, as assigned by Aventis, Inc. to Genzyme Corporation (as amended, the “Sanofi Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/0001193125-22-300162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.